Replies to post #120 on Salarius Pharmaceuticals Inc (SLRX)

[axelvento]

important updates coming soon!

we have money to keep going....


Seclidemstat
Solid tumors
Phase 1 initial efficacy data presented at ASCO June 4, 2021. 7/13 (54%) showed evidence of stable disease after two cycles.



Seclidemstat
Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Phase 1/2 trial to be initiated.

a good bet!